Wealth Enhancement Trust Services
NPCE icon

Wealth Enhancement Trust Services’s Neuropace NPCE Stock Holding History

Wealth Enhancement Trust Services’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-5
Closed -$79 – 1254
2026
Q2 		$79 Buy
+5
New +$80 ﹤0.01% 1429

Other funds holding NPCE

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Wealth Enhancement Trust Services's NPCE Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of Neuropace (NPCE) in Q3 2026, closing a stake of 5 shares — an estimated $79 sold.

Wealth Enhancement Trust Services first reported a position in NPCE in Q2 2026 and held it in 1 quarter. The position peaked at $79 in Q2 2026. 68 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining Neuropace position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 5 Neuropace shares in Q3 2026, an estimated $79.
  • Wealth Enhancement Trust Services first reported a position in Neuropace in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's Neuropace position peaked at $79 in Q2 2026.
  • 68 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.